Article
Oncology
Yuqiu Xu, Guiying Wang, Xuzhi Zheng, Wenju Chang, Jihong Fu, Tao Zhang, Qi Lin, Yang Lv, Zhehui Zhu, Wentao Tang, Jianmin Xu
Summary: Metastasectomy is beneficial for the survival of patients with BRAF V600E mutant-mCRC. For initially unresectable patients, VIC regimen as first-line therapy is associated with better prognosis and efficacy compared to doublet and triplet chemotherapy with or without bevacizumab.
Article
Economics
Paul Peter Schneider, Bram L. Ramaekers, Xavier Pouwels, Sandra Geurts, Khava Ibragimova, Maaike de Boer, Birgit Vriens, Yes van de Wouw, Marien den Boer, Manon Pepels, Vivianne Tjan-Heijnen, Manuela Joore
Summary: This study provides detailed information on hospital resource use and associated costs of patients with advanced breast cancer in The Netherlands. The results show significant variability in lifetime hospital costs, with systemic therapies being the primary cost driver.
Article
Oncology
Shuai Liu, Lu Lu, Feng Pan, Chunsheng Yang, Jing Liang, Jinfeng Liu, Jian Wang, Rong Shen, Fu-Ze Xin, Nan Zhang
Summary: This study retrospectively evaluated the efficacy and safety of oral fruquintinib in mCRC patients, showing consistent clinical activity with previous clinical trials and manageable side effects in real-world settings.
Article
Oncology
Emerik Osterlund, Ari Ristimaki, Markus J. Makinen, Soili Kytola, Juha Kononen, Per Pfeiffer, Leena-Maija Soveri, Mauri Keinanen, Halfdan Sorbye, Luis Nunes, Tapio Salminen, Lasse Nieminen, Aki Uutela, Paivi Halonen, Annika Algars, Jari Sundstrom, Raija Kallio, Raija Ristamaki, Annamarja Lamminmaki, Hanna Stedt, Eetu Heerva, Teijo Kuopio, Tobias Sjoblom, Helena Isoniemi, Bengt Glimelius, Pia Osterlund
Summary: BRAF-V600E mutation is a negative prognostic and predictive biomarker in metastatic colorectal cancer. Non-V600E mutations (aBRAFmt) are rare and poorly understood. This study compared the mutation patterns and characteristics of aBRAFmt with other RAS/BRAF groups in three different cohorts. The study found that aBRAFmt represents a distinct subgroup with differences in clinicopathological features, and its prognosis is slightly better than BRAF-V600E but worse than RASmt and RAS & BRAFwt. aBRAFmt should not be a contraindication for metastasectomy.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Ting Xu, Jian Li, Zhenghang Wang, Xiaotian Zhang, Jun Zhou, Zhihao Lu, Lin Shen, Xicheng Wang
Summary: This study retrospectively analyzed the clinical data of patients between June 2010 and December 2021 and found an association between BRAF V600E mutation and poor and heterogeneous prognosis. First-line intensive chemotherapy had limited impact on progression-free survival and overall survival in patients with BRAF V600E mutant metastatic colorectal cancer.
Article
Oncology
Martin S. Schulz, Sebastian Wolf, Vera Struck, Niklas Thomas, Gabriele Husman, Stefan Zeuzem, Christine Koch, Joerg Trojan, Andreas Anton Schnitzbauer, Wolf Otto Bechstein, Oliver Waidmann
Summary: This real-world study from a large oncology center in Germany provides evidence that anti-EGFR re-exposure may benefit patients with advanced CRC, regardless of the reason for prior discontinuation.
Article
Oncology
Letizia Procaccio, Francesca Bergamo, Francesca Daniel, Cosimo Rasola, Giada Munari, Paola Biason, Stefania Crucitta, Giulia Barsotti, Giulia Zanella, Valentina Angerilli, Cristina Magro, Silvia Paccagnella, Veronica Di Antonio, Fotios Loupakis, Romano Danesi, Vittorina Zagonel, Marzia Del Re, Sara Lonardi, Matteo Fassan
Summary: The study shows that LB testing has a faster turnaround time, with an overall concordance of 83% compared to STB analysis. LB has a high specificity and sensitivity of 90% and 80%, respectively, with a high accuracy in terms of positive and negative predictive values. Interpretation of results should be cautious in LB wild-type cases with low tumor burden.
Article
Oncology
Carles Pericay, Ana Fernandez Montes, Vicente Alonso Orduna, Ismael Macias Declara, Elena Asensio Martinez, Nuria Rodriguez Salas, Esperanza Torres, Diego Cacho Lavin, Rosa Maria Rodriguez Alonso, Esther Falco, Joan Carles Oliva, Lluis Cirera
Summary: The retrospective, observational RWD-ACROSS study examined disease characteristics, treatment, and survival in patients with metastatic colorectal cancer (mCRC) in Spain. The results showed that patients with left-sided tumors and those receiving first-line anti-EGFR or anti-VEGF treatment had longer overall survival.
Review
Health Care Sciences & Services
Ria Garg, Vicki Cheng, Ursula Ellis, Vanay Verma, Helen McTaggart-Cowan, Stuart Peacock, Jonathan M. Loree, Mohsen Sadatsafavi, Mary A. De Vera
Summary: This study conducted a systematic review on the direct medical costs of young-onset colorectal cancer (yCRC) and average-age onset colorectal cancer (aCRC). The findings showed that yCRC has higher medical costs, providing important information for healthcare decisions and considerations for CRC screening among younger adults.
BMC HEALTH SERVICES RESEARCH
(2022)
Article
Oncology
Yan Song, Tao Qu, Honggang Zhang, Yongkun Sun, Chengxu Cui, Yihebali Chi, Wen Zhang, Xingyuan Wang, Lin Yang
Summary: This study aimed to evaluate the safety and effectiveness of fruquintinib in Chinese mCRC patients, with findings showing a relatively low incidence of TRAEs, and consistent PFS and OS results compared to randomized controlled trials. Patients with hypertension or hypothyroidism may experience a potential survival extension of approximately 6 months.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Oncology
Dawei Zhu, Xuefeng Shi, Stephen Nicholas, Yong Ma, Ping He
Summary: This study analyzed the annual prevalence, medical service utilization, and direct treatment costs of lung cancer in urban China, finding that lung cancer imposes a significant economic burden on China's health system and individuals, highlighting the need for specific policies to allocate health resources efficiently and reduce the financial burden on lung cancer patients.
Article
Endocrinology & Metabolism
Min Liu, Jiaqing Yan, Kaidi Le, Ying Li, Nianzeng Xing, Guohui Li
Summary: This study evaluated the incidence and risk factors of adverse events (AEs) in patients treated with abiraterone acetate (AA) and prednisone (PDN) outside clinical trials, and their association with survival outcomes. The results showed that multiple organ metastasis, hypertension, and radiotherapy were associated with worse progression-free survival (PFS). AA was found to be effective and tolerated in real-life settings for asymptomatic or slightly symptomatic metastatic castration-resistant prostate cancer (mCRPC) patients.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Oncology
Olumide Gbolahan, Neda Hashemi-Sadraei, Suri Yash, Grant Williams, Rekha Ramachandran, Young-il Kim, Ravikumar Paluri, Darryl Outlaw, Bassel El-Rayes, Lisle Nabell
Summary: Based on a real-world cohort, this study found that a longer time to treatment initiation (TTI) did not have a negative impact on survival outcomes in metastatic colorectal cancer (mCRC) and metastatic pancreatic cancer (mPC).
Review
Public, Environmental & Occupational Health
N. Bhimani, G. Y. M. Wong, C. Molloy, N. Pavlakis, C. I. Diakos, S. J. Clarke, M. Dieng, T. J. Hugh
Summary: This systematic review examines the direct cost of treating metastatic colorectal cancer and highlights the significant economic burden it places on healthcare systems. The review emphasizes the need for future research to define cost components and examine the relationship between spending, overall survival, and quality of life.
Article
Oncology
Miaomiao Gou, Niansong Qian, Yong Zhang, Huan Yan, Haiyan Si, Zhikuan Wang, Guanghai Dai
Summary: This study aimed to evaluate the efficacy of fruquintinib combined with various PD-1 inhibitors in Chinese patients with refractory mCRC. The results showed that the combination treatment had clinical activity in a small population of heavily pretreated mCRC patients. Further studies with larger sample size are needed to confirm these findings.
FRONTIERS IN ONCOLOGY
(2022)
Article
Cell Biology
Shi Wei, Miaomiao Dai, Chi Zhang, Kai Teng, Fengwei Wang, Hongbo Li, Weipeng Sun, Zihao Feng, Tiebang Kang, Xinyuan Guan, Ruihua Xu, Muyan Cai, Dan Xie
Summary: This study showed that KIF2C is significantly upregulated in HCC and associated with poor prognosis. Functional assays revealed that KIF2C promotes HCC cell proliferation, migration, invasion, and metastasis. Mechanistically, the study identified TBC1D7 as a binding partner of KIF2C, disrupting TSC complex formation and enhancing mTORC1 signaling.
Article
Oncology
Ming-ming He, Zhe Fang, Dong Hang, Feng Wang, Georgios Polychronidis, Liang Wang, Chun-Han Lo, Kai Wang, Rong Zhong, Markus D. Knudsen, Scott G. Smith, Rui-Hua Xu, Mingyang Song
Summary: In a large cohort from the UK Biobank, higher circulating levels of liver function markers, including ALT, AST, TBIL, GGT, TP, and ALB, within the normal range, were associated with a lower risk of colorectal cancer. These findings suggest a potential link between liver function and colorectal cancer, warranting further research on the gut-microbiota-liver axis.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Oncology
Ruihua Xu, Shukui Qin, Weijian Guo, Yuxian Bai, Yanhong Deng, Lei Yang, Zhendong Chen, Haijun Zhong, Hongming Pan, Yongqian Shu, Ying Yuan, Jianfeng Zhou, Nong Xu, Tianshu Liu, Dong Ma, Changping Wu, Ying Cheng, Jianming Xu, Donghui Chen, Wei Li, Sanyuan Sun, Zhuang Yu, Peiguo Cao, Jian Li, Haihui Chen, Jiejun Wang, Shubin Wang, Hongbing Wang, Ning Wang, Bin Zhang, Rubing Han, Weiguo Su, Xiaojun Guo, Jin Li
Summary: The FRESCO study evaluated the efficacy and safety of fruquintinib in metastatic colorectal cancer patients, with a subgroup analysis showing that fruquintinib significantly improved overall survival and progression free survival compared to placebo, regardless of prior targeted therapy. Patients in both subgroups treated with fruquintinib showed measurable reduction in tumor size and disease control with similar side effects, indicating that fruquintinib is safe and effective in both PTT and non-PTT subgroups.
Article
Genetics & Heredity
Wu Jiang, Lin Li, Chuan-Feng Ke, Wei Wang, Bin-Yi Xiao, Ling-Heng Kong, Jing-Hua Tang, Yuan Li, Xiao-Dan Wu, Ying Hu, Wei-Hua Guo, Si-Zhen Wang, De-Sen Wan, Rui-Hua Xu, Zhi-Zhong Pan, Pei-Rong Ding
Summary: This study found that universal germline testing in patients with colorectal cancer can help identify potential hereditary cancer syndromes, especially in those under 70 years old. Enhanced surveillance and tailored treatment may be beneficial for patients with germline pathogenic variants.
JOURNAL OF MEDICAL GENETICS
(2022)
Article
Biotechnology & Applied Microbiology
Cai-Yun He, Le-Zong Chen, Zi-Xian Wang, Li-Ping Sun, Jun-Jie Peng, Min-Qing Wu, Tong-Min Wang, Ya-Qi Li, Xin-Hua Yang, Da-Lei Zhou, Zu-Lu Ye, Jiang-Jun Ma, Xi-Zhao Li, Pei-Fen Zhang, Huai-Qiang Ju, Hai-Yu Mo, Zi-Chen Zhang, Zhao-Lei Zeng, Jian-Yong Shao, Wei-Hua Jia, San-Jun Cai, Yuan Yuan, Rui-Hua Xu
Summary: The research explored the effectiveness of susceptible variants derived from GWAs in optimizing discriminatory accuracy of colorectal cancer (CRC) in Chinese population. A risk predictive model combining 19 variants using statistical method LASSO demonstrated stable performance in three independent centers during validation, suggesting potential for developing individualized CRC prevention strategies in China.
Article
Engineering, Civil
Ruihua Xu, Fangsheng Wang, Feng Zhou
Summary: This study proposes an analysis method of train operation plan based on TTR in the station dimension and applies it to the Beijing metro network as a case study, showing promising results for optimizing the existing train operation plan.
JOURNAL OF ADVANCED TRANSPORTATION
(2021)
Correction
Medicine, Research & Experimental
Feng-Wei Wang, Chen-Hui Cao, Kai Han, Yong-Xiang Zhao, Mu-Yan Cai, Zhi-Cheng Xiang, Jia-Xing Zhang, Jie-Wei Chen, Li-Ping Zhong, Yong Huang, Su-Fang Zhou, Xiao-Han Jin, Xin-Yuan Guan, Rui-Hua Xu, Dan Xie
JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Oncology
Xiuxing Chen, Ziming Du, Mayan Huang, Deshen Wang, William Pat Fong, Jieying Liang, Lei Fan, Yun Wang, Hui Yang, Zhigang Chen, Mingtao Hu, Ruihua Xu, Yuhong Li
Summary: The study suggests that preoperative exosomal PD-L1 (exoPD-L1) and soluble PD-L1 (sPD-L1) levels are associated with the survival of colorectal liver metastasis patients, and are related to T cell infiltration at liver metastases. Tracking exoPD-L1 and sPD-L1 levels could help monitor disease status and detect early recurrence.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Medicine, Research & Experimental
Qi Meng, Yun-Xin Lu, Dan-Yun Ruan, Kai Yu, Yan-Xing Chen, Min Xiao, Yun Wang, Ze-Xian Liu, Rui-Hua Xu, Huai-Qiang Ju, Miao-Zhen Qiu
Summary: The study identified different gastric cancer subtypes with distinct DNA methylation modification patterns, where high DMS was associated with immune activation and favorable prognosis, while low DMS was linked with stromal activation and lack of immune cell infiltration. High DMS was also found to be correlated with enhanced efficacy of immunotherapy.
MOLECULAR THERAPY-NUCLEIC ACIDS
(2021)
Correction
Biochemistry & Molecular Biology
Hai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, Chaosu Hu, Kunyu Yang, Jiyu Wen, Jingao Li, Ying-Rui Shi, Feng Jin, Ruilian Xu, Jianji Pan, Shenhong Qu, Ping Li, Chunhong Hu, Yi-Chun Liu, Yi Jiang, Xia He, Hung-Ming Wang, Wan-Teck Lim, Wangjun Liao, Xiaohui He, Xiaozhong Chen, Zhigang Liu, Xianglin Yuan, Qi Li, Xiaoyan Lin, Shanghua Jing, Yanju Chen, Yin Lu, Ching-Yun Hsieh, Muh-Hwa Yang, Chia-Jui Yen, Jens Samol, Hui Feng, Sheng Yao, Patricia Keegan, Rui-Hua Xu
Article
Oncology
Zhi Peng, Tianshu Liu, Jia Wei, Airong Wang, Yifu He, Liuzhong Yang, Xizhi Zhang, Nanfeng Fan, Suxia Luo, Zhen Li, Kangsheng Gu, Jianwei Lu, Jianming Xu, Qingxia Fan, Ruihua Xu, Liangming Zhang, Enxiao Li, Yuping Sun, Guohua Yu, Chunmei Bai, Yong Liu, Jiangzheng Zeng, Jieer Ying, Xinjun Liang, Nong Xu, Chao Gao, Yongqian Shu, Dong Ma, Guanghai Dai, Shengmian Li, Ting Deng, Yuehong Cui, Jianmin Fang, Yi Ba, Lin Shen
Summary: The study reported the efficacy and safety of a novel anti-HER2 antibody RC48 in patients with HER2-overexpressing gastric cancer, showing promising therapeutic activity and manageable safety, suggesting potential application in patients who have previously received at least two lines of chemotherapy.
CANCER COMMUNICATIONS
(2021)
Review
Oncology
Zi-Hang Chen, Li Lin, Chen-Fei Wu, Chao-Feng Li, Rui-Hua Xu, Ying Sun
Summary: Artificial intelligence, especially deep learning, has been widely applied in the field of oncology, with the potential to enhance cancer diagnosis and treatment. Its applications include early cancer detection, molecular characterization, and personalized treatment.
CANCER COMMUNICATIONS
(2021)
Article
Oncology
Zi-Xian Wang, Chengxu Cui, Jun Yao, Yanqiao Zhang, Mengxia Li, Jifeng Feng, Shujun Yang, Yun Fan, Jianhua Shi, Xizhi Zhang, Lin Shen, Yongqian Shu, Cailian Wang, Tianyang Dai, Teng Mao, Long Chen, Zengqing Guo, Bo Liu, Hongming Pan, Shundong Cang, Yi Jiang, Junye Wang, Min Ye, Zhendong Chen, Da Jiang, Qin Lin, Wei Ren, Junsheng Wang, Lin Wu, Yong Xu, Zhanhui Miao, Meili Sun, Conghua Xie, Ying Liu, Qifeng Wang, Lina Zhao, Qi Li, Canhong Huang, Ke Jiang, Kunyu Yang, Daojun Li, Yunpeng Liu, Zhitu Zhu, Rixin Chen, Liqun Jia, Wei Li, Wangjun Liao, Hong-Xu Liu, Daiyuan Ma, Jie Ma, Yanru Qin, Zhihong Shi, Qichun Wei, Ke Xiao, Yan Zhang, Ying Zhang, Xin Chen, Guanghai Dai, Jianxing He, Junhe Li, Guanghui Li, Yong Liu, Zhihua Liu, Xianglin Yuan, Junping Zhang, Zhichao Fu, Yifu He, Fang Ju, Zheng Liu, Peng Tang, Tiejun Wang, Weibo Wang, Jing Zhang, Xianming Luo, Xiongwen Tang, Rena May, Hui Feng, Sheng Yao, Patricia Keegan, Rui-Hua Xu, Feng Wang
Summary: This study found that toripalimab combined with paclitaxel and cisplatin can significantly improve progression-free survival and overall survival in patients with treatment-naive advanced esophageal squamous cell carcinoma, with manageable safety.
Article
Biochemistry & Molecular Biology
Jin-Fei Lin, Pei-Shan Hu, Yi-Yu Wang, Yue-Tao Tan, Kai Yu, Kun Liao, Qi-Nian Wu, Ting Li, Qi Meng, Jun-Zhong Lin, Ze-Xian Liu, Heng-Ying Pu, Huai-Qiang Ju, Rui-Hua Xu, Miao-Zhen Qiu
Summary: This study reveals the role and regulation mechanism of cysteine desulfurase (NFS1) in the sensitivity of colorectal cancer cells to oxaliplatin. Loss of NFS1 enhances the sensitivity of colorectal cancer cells to oxaliplatin and triggers PANoptosis by increasing intracellular levels of reactive oxygen species (ROS). In addition, high expression of NFS1 is associated with poor survival and chemoresistance in patients with colorectal cancer.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2022)
Correction
Medicine, Research & Experimental
Xiao-Peng Tian, Chen-Yuan Wang, Xiao-Han Jin, Mei Li, Feng-Wei Wang, Wei-Juan Huang, Jing-Ping Yun, Rui-Hua Xu, Qing-Qing Cai, Dan Xie